These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 33269152)

  • 1. Immunotherapy Benefit in a Patient With Non-Small Cell Lung Cancer and a Rare BRAF Mutation.
    Rittberg R; Banerji S; Green S; Qing G; Dawe DE
    Cureus; 2020 Oct; 12(10):e11224. PubMed ID: 33269152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Durable Response to the Combination of Atezolizumab With Platinum-Based Chemotherapy in an Untreated Non-Smoking Lung Adenocarcinoma Patient With
    Niu X; Sun Y; Planchard D; Chiu L; Bai J; Ai X; Lu S
    Front Oncol; 2021; 11():634920. PubMed ID: 34178624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathological features of nonsmall cell lung carcinomas with BRAF mutations.
    Kinno T; Tsuta K; Shiraishi K; Mizukami T; Suzuki M; Yoshida A; Suzuki K; Asamura H; Furuta K; Kohno T; Kushima R
    Ann Oncol; 2014 Jan; 25(1):138-42. PubMed ID: 24297085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Characteristics and Treatment Outcomes of 65 Patients With BRAF-Mutated Non-small Cell Lung Cancer.
    Mu Y; Yang K; Hao X; Wang Y; Wang L; Liu Y; Lin L; Li J; Xing P
    Front Oncol; 2020; 10():603. PubMed ID: 32411601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of EGFR and BRAF mutations by competitive allele-specific TaqMan polymerase chain reaction in lung adenocarcinoma.
    Yang Y; Meng Y; Zhang H; Shen X; Li R; Yu L; Liu B; Wang L
    Oncol Lett; 2018 Mar; 15(3):3295-3304. PubMed ID: 29467863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-L1-negative non-small cell lung cancer harbouring a rare
    Do KH; Nguyen TV; Nguyen Thi Bich P; Nguyen GH; Nguyen CV
    Respirol Case Rep; 2023 Jun; 11(6):e01155. PubMed ID: 37151366
    [No Abstract]   [Full Text] [Related]  

  • 7. Outcomes of non-small cell lung cancer patients with non-V600E
    Lazar R; Fischbach C; Schott R; Somme L
    Front Oncol; 2024; 14():1307882. PubMed ID: 38601760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patients with non-small-cell lung cancer harbouring a
    Auliac JB; Bayle S; Vergnenegre A; Le Caer H; Falchero L; Gervais R; Doubre H; Vinas F; Marin B; Chouaid C
    Curr Oncol; 2018 Oct; 25(5):e398-e402. PubMed ID: 30464690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcomes of non-small-cell lung cancer patients with BRAF mutations: results from the French Cooperative Thoracic Intergroup biomarkers France study.
    Couraud S; Barlesi F; Fontaine-Deraluelle C; Debieuvre D; Merlio JP; Moreau L; Beau-Faller M; Veillon R; Mosser J; Al Freijat F; Bringuier PP; Léna H; Ouafik L; Westeel V; Morel A; Audigier-Valette C; Missy P; Langlais A; Morin F; Souquet PJ; Planchard D;
    Eur J Cancer; 2019 Jul; 116():86-97. PubMed ID: 31181537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations.
    Tissot C; Couraud S; Tanguy R; Bringuier PP; Girard N; Souquet PJ
    Lung Cancer; 2016 Jan; 91():23-8. PubMed ID: 26711930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural Disease History, Outcomes, and Co-mutations in a Series of Patients With BRAF-Mutated Non-small-cell Lung Cancer.
    Myall NJ; Henry S; Wood D; Neal JW; Han SS; Padda SK; Wakelee HA
    Clin Lung Cancer; 2019 Mar; 20(2):e208-e217. PubMed ID: 30442523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coexistence of EGFR, KRAS, BRAF, and PIK3CA Mutations and ALK Rearrangement in a Comprehensive Cohort of 326 Consecutive Spanish Nonsquamous NSCLC Patients.
    Martín Martorell P; Huerta M; Compañ Quilis A; Abellán R; Seda E; Blesa S; Chaves FJ; Dualde Beltrán D; Roselló Keränen S; Franco J; Insa A
    Clin Lung Cancer; 2017 Nov; 18(6):e395-e402. PubMed ID: 28550959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer.
    Nagano T; Tachihara M; Nishimura Y
    Curr Cancer Drug Targets; 2019; 19(8):595-630. PubMed ID: 30526458
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Dong YU; Ren W; Qi J; Jin BO; Li Y; Tao H; Xu R; Li Y; Zhang Q; Han B
    Oncol Lett; 2016 Apr; 11(4):2371-2378. PubMed ID: 27073482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic strategies for BRAF mutation in non-small cell lung cancer: a review.
    Puri M; Gawri K; Dawar R
    Front Oncol; 2023; 13():1141876. PubMed ID: 37645429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting BRAF mutations in non-small cell lung cancer.
    O'Leary CG; Andelkovic V; Ladwa R; Pavlakis N; Zhou C; Hirsch F; Richard D; O'Byrne K
    Transl Lung Cancer Res; 2019 Dec; 8(6):1119-1124. PubMed ID: 32010589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Research Progress of Targeted Therapy for BRAF Mutation 
in Advanced Non-small Cell Lung Cancer].
    Liu X; Zhong D
    Zhongguo Fei Ai Za Zhi; 2018 Aug; 21(8):635-640. PubMed ID: 30172272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management and future directions in non-small cell lung cancer with known activating mutations.
    Gerber DE; Gandhi L; Costa DB
    Am Soc Clin Oncol Educ Book; 2014; ():e353-65. PubMed ID: 24857124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-small-cell lung cancer: how to manage
    Guaitoli G; Zullo L; Tiseo M; Dankner M; Rose AA; Facchinetti F
    Drugs Context; 2023; 12():. PubMed ID: 37168877
    [No Abstract]   [Full Text] [Related]  

  • 20. Targeting non-small cell lung cancer: driver mutation beyond epidermal growth factor mutation and anaplastic lymphoma kinase fusion.
    Chu QS
    Ther Adv Med Oncol; 2020; 12():1758835919895756. PubMed ID: 32047535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.